Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28789405 | 0.86 | HDAC1 (0.58) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL3752732 | 0.83 | HDAC1 (0.78) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| SCHEMBL14453684 | 0.81 | PTGS1 (0.61) | PTGS1HDAC1HDAC2HDAC3RXFP1 | |
| SCHEMBL3762395 | 0.81 | HDAC1 (0.53) | HDAC1HDAC2HDAC3PLK1NCOR2 | |
| SCHEMBL15550450 | 0.80 | HDAC1 (0.72) | PTGS1HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL27040039 | 0.79 | PTGS1 (0.64) | PTGS1HDAC1HDAC2KMT2ARXFP1 | |
| SCHEMBL1236023 | 0.78 | PTGS1 (0.51) | PTGS1HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL3755344 | 0.77 | F10 (0.59) | HDAC1HDAC2HDAC3PLK1HDAC6 | |
| SCHEMBL1233684 | 0.77 | KCNQ3 (0.60) | PTGS1HDAC1KMT2A | |
| SCHEMBL211677 | 0.77 | HDAC1 (0.76) | PTGS1HDAC1HDAC2HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC5 | PTGS1 803/4885HDAC1 1/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.